BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market

Core Viewpoint - The collaboration between BD and Ypsomed aims to enhance self-injection systems for large-volume biologics, improving options for pharmaceutical companies and patients [1][3]. Group 1: Product Development - BD and Ypsomed are developing a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe, which will be compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform [1][2]. - The new syringe features advanced technologies such as an 8-millimeter needle and thinner wall cannulas, designed to support the delivery of higher volume and viscosity medicines [2][4]. - The syringe aims to maximize flow efficiency and reduce injection time, addressing challenges associated with large-volume biologics [4][5]. Group 2: Market Demand and Applications - There is a growing demand for patient-friendly solutions in the high-dose biologics space, particularly in oncology, autoimmune diseases, rare diseases, and metabolic disorders [3][5]. - Ypsomed's YpsoMate® 5.5, introduced in 2022, was developed to meet the needs of patients requiring large-volume subcutaneous injections, featuring an ergonomic design and intuitive activation [3][5]. Group 3: Strategic Collaboration - BD and Ypsomed have a history of collaboration, previously developing the 2.25 mL version of the Neopak™ XtraFlow™ Syringe and YpsoMate® 2.25 autoinjector, which demonstrated improved flow and optimized injection times [5]. - The partnership is focused on expanding the subcutaneous delivery design space to accommodate high-dose therapies, enhancing the development of combination products and reducing time-to-market for pharmaceutical companies [5][6]. Group 4: Future Outlook - The BD Neopak™ XtraFlow™ 5.5 mL Glass Prefillable Syringe is currently in development and will undergo comprehensive testing for compatibility with the YpsoMate® 5.5 platform, with samples expected for feasibility studies in mid-2026 [6].